| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000033829 |
| Receipt No. | R000038545 |
| Official scientific title of the study | Berberine containing quadruple therapy for initial Helicobacter Pylori eradication |
| Date of disclosure of the study information | 2018/08/20 |
| Last modified on | 2018/08/20 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Berberine containing quadruple therapy for initial Helicobacter Pylori eradication | |
| Title of the study (Brief title) | Berberine containing therapy for Helicobacter Pylori | |
| Region |
|
|
| Condition | ||
| Condition | H. pylori infection | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the therapy efficacy (eradication rate) and safety between Bismuth Containing Quadruple Therapy (BCQT) and Berberine Containing Therapy (BCQT plus berberine) |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | eradication rate of H. pylori |
| Key secondary outcomes | side effects rate during therapy |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Berberine Containing Therapy (Berberine 0.3g tid, Rabeprazole 10mg bid, Bismuth 500mg bid, Amoxicillin 1g bid and Clarithromycin 500mg bid) for 14 days | |
| Interventions/Control_2 | Bismuth Containing Quadruple Therapy (Rabeprazole 10mg bid, Bismuth 500mg bid, Amoxicillin 1g bid and Clarithromycin 500mg bid) for 14 days | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients positive to Rapid Urease Test
Patients positive to 13C Urease Breath Test Patients verified of Hp infection with pathology |
|||
| Key exclusion criteria | Patients with allergy history of drugs medicated in this trail
Patients with history of hepatic or/and renal dysfunction Patients with history of operation on upper digestive tract Patients with alcoholism and drug abuse Patients in pregnancy or lactation Patients who ever participated other clinical trials in latest 3 months Patients with previous eradication therapy; |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Yu Lan |
| Organization | Beijing Jishuitan Hospital |
| Division name | Departement of Gastroenterology |
| Address | No. 31, Xinjiekou East Street, Beijing |
| TEL | 86-10-58398289 |
| lanyu-mail@sohu.com | |
| Public contact | |
| Name of contact person | Xiaobei Si |
| Organization | Beijing Jishuitan Hospital |
| Division name | Departement of Gastroenterology |
| Address | No. 31, Xinjiekou East Street, Beijing |
| TEL | 86-10-58398289 |
| Homepage URL | |
| sixiaobei2008@126.com | |
| Sponsor | |
| Institute | Health bureau of Beijing |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Administration of traditional Chinese medicine of Beijing |
| Organization | |
| Division | |
| Category of Funding Organization | Government offices of other countries |
| Nationality of Funding Organization | P. R. China |
| Other related organizations | |
| Co-sponsor | No |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | Beijing Jishuitan Hospital (Beijing) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038545 |